Abstract: Drug cost projections for 2001 and factors that are likely to influence drug costs are discussed.
T
he year 2000 opened to the sound of the general public and politicians focusing on the high cost of drugs and the inability of patients to afford their prescription needs. In an election year, the pharmaceutical industry became an easy target for controversy.
One of the outspoken critics of the industry is U.S. Representative Bernard Sanders (I-VT), who has taken elderly constituents to Canada to buy prescription drugs. He has encouraged legislation in the U.S. House of Representatives to allow American pharmacists and distributors to reimport drugs approved by FDA from Canada and Mexico and has set up a Web site focusing on the inequities of American drug pricing. 1 Maine's legislature approved, and the state's governor signed into law, a bill to enter into rebate agreements with manufacturers to provide discounted drugs for residents who do not have prescription drug insurance. 2 The law directs that there be negotiated rebates at the level of the federal Medicaid program by January 1, 2001 . By July 1, 2003, if Maine is paying more for drugs than other large purchasers are, the state would impose "even more stringent retail pharmacy price controls." California has enacted legislation that mandates California pharmacists who participate in Medi-Cal to charge Medicare enrollees without prescription coverage the Medi-Cal prescription price. 3 At this writing, approximately 16 states, including Arizona, Illinois, New Jersey, and New York, are studying ways or considering legislation to control drug costs. 4 The issue causing the high level of activity to control costs, at both the federal and state levels, is the backlash against what is considered to be the high cost of drugs.
In 1999 the pharmaceutical industry had sales of nearly $122 billion, up 19% from the preceding year ac-cording to IMS Health, a company that conducts market research on the pharmaceutical industry. 5 Chain drugstores accounted for 30% of all prescription drug purchases, while hospitals accounted for 12.4%, representing a decrease of 1% compared with 1998. Clinics accounted for 6.7% of total drug purchases and had the highest percent increase of any group, 27%, compared with the previous year. Long-term care maintained 4% of total market purchases. Domestic sales of drugs are expected to be over $105.6 billion in 2000, up 11.2% from 1999; sales abroad are estimated at $43.6 billion, up 3% from 1999; and total sales will increase to $149.8 billion in 2000, up 11.2%. 6 For hospitals, outpatient visits grew 5.3%, compared with a less than 1% increase in inpatient admissions. Hospital outpatient prices for prescription drugs increased 6.1%, representing the largest increase in the past seven years. 7 Hospital operating profits continued to decrease in 1999, falling 27%. 8 This follows a decrease of 28% in 1998. In the two-year period from 1997 to 1999, the average hospital's operating profit decreased 50%, from 6.1% to 3.2%. This has occurred while expenses are keeping pace with inflation but operating revenues are not experiencing any growth. The Northeast experienced operating profits of 0% in 1999, down from 3.7% in 1997. The South Atlantic and North Central regions had the highest operating profits, 4.42% and 4.16% for the year, respectively, while the South Central and West regions were intermediate, at 2.15% and 3.75%, respectively. Hospitals with less than 150 beds had the best profit margins, 4.19%, while those with over 300 beds had the worst, 2.69%; hospitals with 150-300 beds were intermediate, at 3.07%. At the same time, retail prices at the nation's hospitals rose 5.1% in 1999, compared with a 2.7% inflation rate for all goods and services. 9 In view of the above findings, it is not difficult to understand why hospitals, among other health care providers, are under great financial pressures. These changes have been occurring at the same time that health care spending has increased to over $1.1 trillion for 1999. 10 During 1999 and the first quarter of 2000, the merger movement among hospitals slowed and some of the most notable planned mergers, such as those involving Penn State, Geisinger Health System, Optima Health, and Stanford Health System, have broken up or are in the final stages of breaking up. Among the stated causes are that financial goals were not met, that cultures clashed, and that there were ethical problems.
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In 1999 PricewaterhouseCoopers predicted that pharmaceutical companies must generate blockbuster drugs, enter restructured markets, or merge to remain viable and that the number of top firms would be reduced to 13 by 2005. 12 The prediction may be accurate, but the time element in which it would occur appears to have been shortened by the mergers that took place in 1999 and 2000.
2000 began with pharmaceutical industry consolidations further decreasing the number of independent, major pharmaceutical companies. Glaxo Wellcome and SmithKline Beecham joined to form GlaxoSmithKline. Thus the names "Wellcome" and "Beecham," both so well-known, disappeared, and the largest pharmaceutical company in the world was formed. Pfizer merged with Warner-Lambert, which became a division of Pfizer Inc. This merger formed a company with a $4.7 billion investment in research and development (R&D), the largest expenditure for R&D in the industry. Pharmacia & Upjohn merged with Monsanto and became known as the Pharmacia Corporation. The name of Upjohn is no longer listed on the pharmaceutical landscape. G. D. Searle, a division of Monsanto, also joined the Pharmacia group as a subsidiary. Pharmacia thus became a member of the top-10 pharmaceutical company club and has set as its goal becoming the best-managed company in the industry. 13 American Home Products, which lost out to Pfizer in the bidding for Warner-Lambert, is said to be looking for a partner in order to survive as a major player in the field. The same concern for survival holds for other major pharmaceutical companies, such as Bristol-Myers Squibb. The reasons for all this activity are to produce new, effective medications and to enter the consumer market quickly. The mergers of Glaxo Wellcome and SmithKline Beecham, Pfizer and Warner-Lambert, and Pharmacia & Upjohn and Monsanto add to those that produced Aventis, Novartis, and AstraZeneca. It must be asked whether the industry will now introduce exciting new drugs faster and whether drug prices will rise as a result of decreasing competition. Government control of drug prices could hinge on the answers to these questions.
Among the significant transformations taking place in the pharmaceutical market is a change in the marketplace itself. PACE Alliance, a 220-member independent pharmacy buying group, has agreed to purchase pharmaceutical products through the business-to-business Web site Rxmarketplace.com.
14 Bergen Brunswig is shipping 25,000 direct-to-customer orders per week through its new Internet fulfillment center. 15 Drugstore.com, through its partnership with Amazon.com, has increased traffic to its site 20-30%. 16 Drugstore.com added 295,000 new customers during the first quarter of 2000, a 42% increase over the preceding quarter. The Web site now has a total of 990,000 customers.
These changes are reflective of a market undergoing major changes. The issues facing pharmacy and the pharmaceutical industry are how the market should operate and how it will function in the future. 22 The cuts will come from eliminating duplications and overlaps in administration and research. Since all three of these mergers include companies already on this list, the total dollars spent by the top 10 for R&D will increase significantly in 2000. 13 Of further interest, only four companies on the list have not merged as of this writing: Merck, Eli Lilly, Schering-Plough, and American Home Products.
With respect to total nationwide spending on R&D, aside from approximately $24 billion spent by the pharmaceutical industry, FDA spent $1.3 billion and the National Institutes of Health spent an additional $15.6 billion on R&D. 23 These additional expenditures dramatically increased the dollar investment on R&D in the United States in 1999.
There are predictions that in the future fewer blockbuster drugs will be released because of the shift from treating patients to attempting to keep people healthy. Included in the definition of keeping people healthy is the modification of new-drug pipelines to incorporate more life-enhancing drugs. Pfizer's Viagra (sildenafil) is one of the first of these drugs to be a major success. Other examples include Merck's Propecia (finasteride) for hair loss and a drug being developed for acne, while Pharmacia is working to allow for oncedaily administration of some of its drugs. 24 New opportunities also exist in such areas as genome research that will further change the direction of R&D and drug therapy and may lead to new, better-directed therapeutic agents.
A study by the University of Maryland for the Health Insurance Association of America predicts that "pipeline" pharmaceuticals will be responsible for 40% of the annual increase in drug expenditures over the next five years. 25 Drugs currently in development will account for $42.8 billion of a $107 billion increase in pharmaceutical spending. The remaining $62.2 billion will be due to price increases and greater utilization of currently marketed drugs. The yearly increase in spending for pharmaceuticals will be 15-18% over the next five years. Should this prediction prove accurate, it will reemphasize the importance of managers to proactively (1) track drugs in the pipeline that are likely to be used in their practice setting and (2) track the changes in utilization and expanded use of currently marketed products to better assess the effect of price increases.
Of equal importance and concern are the adverse effects of new drugs that negatively impact both patient care and drug costs. These problems 
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are highlighted by FDA's withdrawal of troglitazone, which was introduced in 1997 as a new treatment for type 2 diabetes mellitus. In March 2000, FDA withdrew the drug from the market because of reports of sudden liver failure in 90 patients, 63 of whom died. With the introduction of rosiglitazone and pioglitazone, FDA convened a meeting to discuss the withdrawal of troglitazone and to warn of a similar potential adverse reaction to the two newly released drugs. What is unusual is that FDA withdrew troglitazone without consulting its advisory panel, which had recommended keeping the drug on the market with restrictions, and held a meeting to discuss the withdrawal after the fact. 26 Is FDA changing its approach to the problem of drug recalls? Was FDA successful in acting quickly, or did it fail because patients died? FDA is very concerned that adverse-effect warnings on product packages and labeling are not enough to ensure patient safety. Therefore, FDA is beginning to agree with manufacturers that restricted-distribution mechanisms are needed to minimize serious adverse effects for selected high-risk drugs (e.g., dofetilide). If such mechanisms result in far fewer adverse effects, pharmacists should expect that these types of arrangements will be repeated for other newly marketed high-risk drugs.
On May 23, 2000, the Clinton administration announced that the Department of Health and Human Services would be taking new steps to strengthen federal oversight over and increase the accountability of researchers conducting clinical trials with human subjects. 27 Among the actions proposed were (1) requiring researchers to undergo training in standard ethics and human subjects research before funds are granted, (2) requiring institutional review boards to conduct audits to determine if informed consent has been obtained, (3) providing for widespread review of the informed-consent process, and (4) imposing civil penalties of up to $250,000 for individual researchers and $1 million for institutions for repeated violations of current regulations. The intent is to safeguard patients in clinical trials and place additional responsibility on investigators and hospitals.
On January 1, 2000, FDA began to release information to the public that had been submitted by drug manufacturers for review by advisory committees. The information submitted for consideration includes statistical summaries of safety, names of principal investigators, proposed indications, dosages, and routes of administration. As of January 1, FDA began posting this information on its Web site (www.fda.gov). Before this change, the information was not available until after the drug was approved.
The Public Citizen Health Research Group sued FDA in 1999 to make the information available to the public. 28 The Pharmaceutical Research and Manufacturers of America (PhRMA) seeks to limit the amount of information FDA releases. It is concerned that the current draft guidelines may result in publicizing of manufacturers' trade secrets. However, it should be noted that commercial confidential information, including product formulation and manufacturing information, is exempt from public disclosure under the current draft guidelines.
New drug approvals
By the end of July 2000, the number of new drug approvals in 2000 was 37 Table 2 . 30 Drugs being considered for approval include products for depression, irritablebowel syndrome, Alzheimer's disease, colorectal cancer, and migraine headache. The possibilities for future drug approvals include individually tailored gene therapies, products to correct DNA problems, and cures for several diseases thought to be incurable. 31 The therapeutic category with the largest number of drugs awaiting approval in 2000 is cancer drugs, followed by central-nervous-system drugs and anti-infective drugs.
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SmithKline Beecham had the most products awaiting approval, followed by Aventis, Lilly, and Glaxo Wellcome. 32 Information on classifications and ratings of newly approved or approvable drugs can be obtained by contacting the FDA Center for Drug Evaluation and Research, Rockville, Maryland (301-594-1012 or www.fda.gov).
Generic drugs
The generic drug industry is an important factor in the pricing and cost of prescription drugs, but the future of the industry is unclear. It is anticipated that many blockbuster drugs will be coming off patent within the next few years. By 2005, drugs that will have lost their patent protection include Prilosec (omeprazole), Zocor (simvastatin), Vasotec (enalapril), Pravachol (pravastatin), and Glucophage (metformin). These drugs are among the major medications for chronic diseases; their total sales value is estimated to be $40 billion. 33 One projection has indicated that the generic industry's sales may be over $20 billion by the year 2005, up from an estimated $13 billion in 2000. 34 It is believed that the Baby Boomers will be a more budget-conscious and computer-savvy group of drug purchasers than were their parents. 34 In a recent survey by MerckMedco, 87% of respondents said they would buy a generic drug over a brand-name drug. 33 In another recent study, the percentage of patients who believed that generic drugs were riskier than brand-name drugs varied from 14.2% to 53.8%. 35 The perceived risk of generic versus brandname products varied with the condition being treated. Generics were most frequently seen as risky by heart disease patients (53.8%), while only 14.2% of patients using generic drugs for cough saw them as risky. Although this study had limitations (e.g., a sample from one small area of one state), there appeared to be a relationship between cost and risk.
The 
Future drug expenditures SPECIAL FEATURES
pay $100 million to states and $8 million in lawyer fees to settle federal and state antitrust charges. 38 The case concerned charges that in 1998 Mylan increased the price of clorazepate from $11.36 to $377 for a 500-tablet supply and the price of lorazepam from $7.30 to $191.50 for 500 tablets.
FDA's Office of Generic Drugs (OGD) has estimated that it may approve 315 generic drug applications in 2000, compared with 242 in 1999-a 30% increase. 39 The limited approvals during 1999 may have resulted from mergers between generic companies. FDA's intent is to have most applications reviewed within a 180-day time frame, according to the acting director of the OGD, Gary Buehler. With the availability of generic brands of important pharmaceuticals, as demonstrated by the approval of generic brands of midazolam and propofol in 2000, one can expect significant price decreases for both the generic and brand-name drugs. The generic industry is growing in importance and size and will continue to do so. If drug coverage for the elderly and Medicare patients becomes a reality, one can expect greater growth than in the past.
Increasing drug costs
The increasing cost of drugs can be traced to a number of factors causing a higher level of spending for pharmaceuticals. Among the factors are new and expensive drugs, broader health-insurance coverage, the availability of drugs for which no therapy was available in the past, a shift from other therapeutic modalities to drug therapy, and increased consumer demand driven by direct-to-consumer advertising. Data indicate that drug companies spent $5.7 billion on detailing in 1998, a 15% increase over 1997. 40 In addition, after the introduction of some major new drug classes (e.g., lipid-lowering drugs and low-molecular-weight heparins), drugs have been found to be effective for conditions other than the approved indications and may be recommended for patients in the same diagnostic categories who were thought not to be candidates when the drugs were introduced.
Spending on prescription drugs was estimated to be over $112 billion in 1999 and to account for more than 8% of total national health expenditures. 41 It is anticipated that by 2008 expenditures will increase to $243 billion and will consume 12.6% of total health care spending. Spending on prescription drugs is increasing at a rate of 12% per year and is predicted to increase 10% annually for the next eight years. IMS Health has projected an average global sales growth of 8.1% per year to 2004, expanding the global market to $506 billion. 42 North America was the world's largest market in 1999, with sales of $138.8 billion, a growth rate of 18%, and projected average yearly increases in growth of 11% until 2004. It should be noted that projections of sales and expenditures vary, depending on the period of estimation during a given year.
A study by Express Scripts found that prescription drug spending increased by a record 17.4% in 1999. 43 The overall average cost per prescription increased by 9.6%. The average cost per prescription increased by 14% for people 70 to 79 years of age and 16.4% for those 80 or older. Approximately 50% of the increase was due to higher costs for the typical prescription, and 50% was due to increased use of prescription drugs and the introduction of new drugs. This study raises important questions concerning the pharmaceutical industry's pricing practices.
According to the Lazarus report, containing information from 45 well-known hospitals, drugs accounted for 80.5% of pharmacy costs in 1999, compared with 75.1% in 1998. 44 Drug expenditures were up 18.1% on average, versus 14.4% in 1998, while the average cost per patient-day was $98.62. The cost was $65.50 per patient-day for the lowest quartile and $111 for the highest.
Hospitals with outpatient prescription departments had an average increase of 22.6% in ambulatory care drug costs in 1999.
All the forecasts being made may be considered to be bullish in anticipation of expensive new drugs coming onto the market. Should health care reform be introduced and include a drug coverage program, sales may not reach the levels anticipated. In addition, patent expirations over the next few years may reduce sales growth.
Another view is one that predicts the introduction of more blockbuster drugs, offsetting lost revenue from patent expirations. In addition, drugs developed through pharmacogenetics research and other scientific breakthroughs will provide innovative new therapies. Anderson Consulting has predicted that the pharmaceutical industry will quadruple the number of drug launches each year by 2008. 45 This will be accomplished by reducing to 10% from 30% the number of experimental drugs that never reach the market.
Pharmacists' responsibility
What responsibility do pharmacists have regarding drug costs? It is obvious to legislators, the public at large, and health care providers that the cost of drugs is continuing to increase. The cost in some instances is beyond what patients can afford and yet continues to increase.
Various attempts have been made by pharmacists, or are being introduced, that may limit-but probably not decrease-drug costs. The formulary system was one of the first methods of controlling costs, followed by clinical pharmacy involvement, drug rounds, switching from i.v. to oral dosage forms, restricting the use of selected drugs, and using generic products. Trying a less expensive drug first (e.g., prescribing a histamine H 2 -receptor blocker before using a proton-pump inhibitor), requiring copayments, and not covering "lifestyle drugs," such as sildena-
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fil, are other methods in place to control costs, but the fact remains that costs continue to escalate.
Some additional alternatives include reducing R&D spending, using only generic drugs when available, restricting company advertising and detailing, imposing price controls, pricing drugs on the basis of ability to pay, and equalizing drug costs throughout the world. Although there may be more alternatives, no one good alternative has been presented that would not have a detrimental effect on the patient or the industry's ability to introduce important new pharmaceuticals.
Perhaps we have reached the point where a national formulary tied to firm, nationwide standards is required. Unprejudiced reviews of large-scale drug use may need to be undertaken to determine how effective agents are and whether in fact drugs reduce other health care costs (e.g., length of stay for hospital inpatients). Whether FDA needs to approve another "me-too" drug might be questioned. How many nonsteroidal anti-inflammatory or lipid-lowering drugs are required? Have we reached the point where decisions must be made as to which duplicate products should or should not remain on the market? What does appear to be necessary is that a national program be established that will not discourage innovation by the pharmaceutical industry and that will at the same time provide the drugs necessary for treating people at an affordable cost.
Prescription versus nonprescription status
Among the important changes that will continue to affect health care during 2001 are direct-to-consumer advertising, the growing use of herbal products, and the greater availability of medical information to patients. These changes have led to more patients managing their own treatment.
In May 2000, FDA announced it would begin reviewing drugs for chronic conditions that should be available without a prescription. The agency was interested in determining new candidates for nonprescription status. 46 FDA requires that nonprescription drugs treat conditions that a consumer can diagnose without a physician's involvement and that labeling be understandable and correct. PhRMA is not in favor of any changes in the current system, probably because nonprescription drugs are less profitable than prescription drugs. From the viewpoint of hospitals, managed care companies, and other systems that dispense drugs, such a change could provide a significant reduction in drug costs to many drug dispensers.
For the first time since 1972, when 600 drugs were switched from prescription to nonprescription status, FDA is reviewing nonprescription drug regulations with an eye to creating a new system for approving nonprescription status for prescription drugs. 47 An agency official leading the review recognized patients' growing interest in self-care. However, concern about patient harm must be raised when defining minor conditions. Among the drug classes being reviewed are cholesterol-lowering drugs, antibiotics, and birth-control products. Sidney Wolfe of the Public Citizen Health Research Group has stated his objection to some of the classes suggested for change. Others have suggested that the agency follow Canada's system of "under-thecounter" drugs-drugs that do not require a prescription but that require pharmacist involvement before those that are potentially dangerous may be sold. Thus, action taken by FDA may be favorable by lowering the cost of drugs to many pharmacy facilities or by having pharmacists control a third class of drugs.
In June 2000, health plans, large employers, unions, and consumer advocates formed a coalition, Rx Health Value, consisting of 83 million members, designed to slow the increase in spending for prescription drugs. 48 Plans for the coalition to cut drug costs include sharing information obtained from independent studies to identify the most effective agents and to increase consumers' political influence on drug matters. The coalition pointed out that the pharmaceutical industry spent $13.9 billion to market drugs in 1999, 50% more than in 1996, when direct-toconsumer advertising was approved. An organization, Rx Intelligence, sponsored by Blue Cross, will undertake clinical studies to determine which new drugs are an improvement over existing drugs. The goal of the coalition is to have "enough heft so it can speak with a voice equal to the pharmaceutical industry's," said John Golenski, executive director of the new group.
Gene therapy
In June 2000 it was announced that sequencing of the human genome had been completed. It was recognized that the first practical impact of this finding would be in the health care field; medicine as we know it will dramatically change. 49, 50 Directing cells to repair damaged tissue and interact with foreign bodies and tailoring medications to treat and prevent medical problems in individual patients may become everyday events. It can be anticipated that there will be a great deal of activity to produce new therapeutic agents that will be expensive and at times unaffordable by many patients. In the near future, such agents will have limited use and will probably not be a major factor in the overall cost of drug therapy. However, should the R&D cost of these new agents exceed what the pharmaceutical industry anticipates, their introduction may increase the cost of agents currently on the market.
What lies ahead
Concerns about drug prices have escalated to a point beyond what we have ever witnessed before. Several responses of the pharmaceutical mar- A variety of new companies are starting to offer below-market prices on prescription drugs and on services such as physician, dental, and eye care and medical tests. 51 People sign up as if joining a discount club like Costco or Sam's Club, pay a small annual membership fee, and purchase drugs and services from pharmacies and other sources that have agreed to charge lower prices.
Medicare's new prospective pricing system for hospital outpatients uses an ambulatory payment classification (APC) system to divide services into 451 groups. Payment is adjusted on the basis of geographic location. Reimbursement is based on J codes (revenue codes) for each drug covered by the program. With the exception of J-coded drugs, drugs are bundled into the cost of major procedures.
As of this writing, the U.S. House of Representatives and the U.S. Senate have passed amendments to the Agriculture, Rural Development, FDA, and Related Agencies Appropriation Bill (H.R. 4461). 52 The Senate version is slightly more restrictive than the House version and would allow pharmacists and drug wholesalers to import FDA-approved prescription drugs from other countries. Under the Senate amendment, consumers would still be restricted from importing prescription drugs into the United States.
Maine's drug-pricing law is being considered by an alliance of 21 states that support the Prescription Drug Fair Pricing Act. 53 Florida is now in the earliest stages of the legislative process and hopes to introduce a bill in the next legislative session. PhRMA has called the law unconstitutional and has filed a lawsuit in U.S. District Court in Bangor, Maine. PhRMA said that the state is reaching outside its borders to require discounts from out-of-state manufacturers.
The Clinton administration plans to cut payments for anticancer drugs administered to patients in physicians' offices. 54 Secretary of Health and Human Services Donna Shalala has justified this action on the basis of frequent overcharging for drugs, mainly for Medicare patients. It has been suggested that patients would be sent to hospitals for treatment.
Drug cost coverage for the elderly or for Medicare patients is a hotly debated public policy issue. Passage of legislation approving such coverage by any drug plan would significantly alter the landscape of drug utilization and costs. 55 
Conclusion
The last months of 2000 and the year 2001 will bring many changes within the pharmaceutical industry and thus increased changes in the purchasing and utilization of drugs within the United States.
There are about 530 new products and new indications awaiting approval for marketing, and an additional 970 new products and new indications are in Phase III trials. 56 It is expected that the 1500 new products and indications will be approved within the next three years. The U.S. pharmaceutical industry will spend $27.4 billion for R&D in 2000, and sales are expected to be $149.1 billion, an 11.2% increase over the 1999 figure. Although there has been a decrease in productivity due to increased clinical development costs, it is forecast that declines in productivity will not continue.
Drug benefit costs for large employers are expected to increase 23.4% over the next year for retirees, and new drugs will have increased utilization, leading to higher prescription costs. 57, 58 Americans over age 65 have seen the average cost of a prescription increase from $28.50 in 1992 to $42.30 in July 2000. It is predicted that the average cost per prescription will increase to $72.94 by 2010.
Spending on prescription drugs averaged $387.09 per person in 1999, an increase of 17.4%. 59 The major reasons for the 1999 increase and the continuing increase in 2000 were higher prices and greater utilization. New drugs introduced since 1992 accounted for 40.8% of 1999 costs but only 25.4% of prescription drug use. Although the increase in drug prices affected all drug classes, the largest cost increases were due to increased utilization. Antihyperlipidemics ranked first, followed by antidepressants, GI drugs, and antihistamines.
IMS Health has determined that, of the total increase in the cost of drugs in 1999, 10.8% was due to increased use of existing drugs, 4.2% to increased prices of existing drugs, and only 3.8% to new drugs. 40 Since 1990 there has been a change in the cause of increased drug costs. Price increases for existing drugs accounted for 4.8% of the total drug cost increase and new drugs for 1.4%. However, the main cause of increased costs since 1994 has been the increased use of existing drugs. In budgeting for 2001, it would be prudent to consider the increased use of existing drugs to be the major factor in spiraling costs.
The 1999 Lazarus report, a survey of 42 hospitals from across the country, found that drug expenditures accounted for 80.5% of pharmacy expenditures, compared with 75% in 1998. 44 Drug costs had increased 18.1% and the cost per case 3.2%. The projection of an annual increase of 11.2% into 2001 by IMS Health indicates that we can anticipate increased drug costs in 2001. 60 We project that drug cost increases in 2001 will range from 11% to 15%, depending on the area of practice. Increased drug utilization will probably have a more significant effect on total drug costs than new, more expensive drugs. The major unknown is what actions federal and state governments will take to control prescription drug prices.
